Drug and Therapeutics Bulletin 1995;33:19-21; doi:10.1136/dtb.1995.33319
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Finasteride and benign prostatic hyperplasia

Relevant BNF sections: 6.4.2, 7.4.1

Finasteride (Proscar - MSD), a type II 5{alpha}-reductase inhibitor, was introduced in 1992 for the medical treatment of men with benign prostatic hyperplasia. The manufacturer claims that finasteride can "halt the progress of the disease and reverse the disease process" and that "one year of therapy with finasteride reversed more than 15 years' growth in prostate volume". We examine the clinical effectiveness of finasteride and assess these claims.




This article has been cited by other articles:


Home page
 BMJHome page
P. Vallance
Drugs and the fetus
BMJ, April 27, 1996; 312(7038): 1053 - 1054.
[Full Text]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.